AS
60 programs · 58 companies
Programs
60
Companies
58
Trials
46
MOAs
36
PI3KiPCSK9iMDM2iKRASG12CiBCMA ADCKIF18AiCDK4/6iCAR-T BCMAIL-13iWEE1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Phase 3 | SHP2 | ||
| Ribofutibatinib | Phase 2/3 | SOS1 | ||
| BMY-8678 | Approved | RET | ||
| Pexazasiran | Preclinical | FXIa | ||
| Olpatinib | Preclinical | PD-L1 | ||
| BMR-8526 | Phase 1/2 | CD38 | ||
| ION-8812 | Phase 1 | MALT1 | ||
| JAZ-8729 | Phase 2/3 | FcRn | ||
| ROI-3353 | Phase 1/2 | PLK4 | ||
| MDG-611 | Approved | CGRP | ||
| KYM-8808 | Phase 1/2 | TIGIT | ||
| Talazumab | Phase 1/2 | WEE1 | ||
| PAS-2221 | Preclinical | GPRC5D | ||
| Riboderotide | Phase 2 | PSMA | ||
| Nirabrutinib | Phase 2 | DLL3 | ||
| 600-1653 | NDA/BLA | GLP-1R | ||
| CIP-2846 | Phase 3 | MALT1 | ||
| 187-151 | Phase 1 | Aβ | ||
| TEM-5063 | Preclinical | SGLT2 | ||
| CHA-IIT-687 | Phase 1 | AuroraA | ||
| SAM-IIT-636 | NDA/BLA | MDM2 | ||
| Pexaderotide | Phase 1/2 | APOC3 | ||
| FOR-4809 | Phase 1 | PLK4 | ||
| FOR-9610 | Phase 2 | TYK2 | ||
| KAL-3824 | Phase 1/2 | FLT3 | ||
| NUR-9873 | Phase 3 | TROP-2 | ||
| Lirarasimod | Phase 1/2 | TYK2 | ||
| Voxasotorasib | Phase 3 | CD38 | ||
| ELI-3182 | Preclinical | PLK4 | ||
| 601-7487 | Phase 2 | Menin | ||
| Voxatapinarof | Phase 2 | PARP | ||
| MOM-980 | Preclinical | TYK2 | ||
| Lirazumab | Phase 2 | FXIa | ||
| BIG-7200 | Phase 1 | KRASG12D | ||
| VAL-6020 | Phase 2/3 | JAK2 | ||
| Talazasiran | Approved | PLK4 | ||
| Mirirelsin | Phase 1/2 | IL-13 | ||
| Mavuzanubrutinib | Phase 1/2 | IL-17A | ||
| Datotuximab | Phase 1/2 | TROP-2 | ||
| Doxafotisoran | Phase 3 | LAG-3 | ||
| Lisotenlimab | Phase 1/2 | DLL3 | ||
| RNA-5263 | Phase 1/2 | CGRP | ||
| Zanumavacamten | Phase 1/2 | DLL3 | ||
| Motanaritide | NDA/BLA | Aβ | ||
| VAL-183 | Phase 2 | PRMT5 | ||
| MRK-6740 | Phase 2/3 | B7-H3 | ||
| BER-3725 | Phase 3 | FXIa | ||
| Rimasotorasib | Phase 1/2 | WRN | ||
| NEO-620 | Phase 2/3 | IL-13 | ||
| TOL-8761 | Phase 2 | EGFR | ||
| Lisonaritide | Phase 1/2 | AuroraA | ||
| NTC-6338 | Approved | FXIa | ||
| Lisozumab | Phase 2/3 | Menin | ||
| LAB-8428 | Phase 2 | IL-23 | ||
| Pexatinib | Phase 3 | PI3Kα | ||
| Teralucimab | Phase 1 | CD19 | ||
| Elralucimab | Phase 1/2 | SOS1 | ||
| ZTS-9629 | Phase 3 | CFTR | ||
| ZHE-6042 | Phase 2 | FXIa | ||
| 453-180 | Phase 3 | TIM-3 |
Trials (46)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04127495 | Ribofutibatinib | Phase 2/3 | Not yet recr... |
| NCT04148716 | BMY-8678 | Approved | Terminated |
| NCT05418684 | BMY-8678 | Approved | Recruiting |
| NCT08457894 | BMY-8678 | Approved | Recruiting |
| NCT05429092 | BMY-8678 | Approved | Active |
| NCT05598919 | Pexazasiran | Preclinical | Terminated |
| NCT03313636 | BMR-8526 | Phase 1/2 | Terminated |
| NCT03161357 | JAZ-8729 | Phase 2/3 | Completed |
| NCT05905540 | JAZ-8729 | Phase 2/3 | Recruiting |
| NCT07145432 | ROI-3353 | Phase 1/2 | Not yet recr... |
| NCT07364829 | MDG-611 | Approved | Recruiting |
| NCT05946838 | MDG-611 | Approved | Recruiting |
| NCT03178810 | KYM-8808 | Phase 1/2 | Completed |
| NCT04250895 | KYM-8808 | Phase 1/2 | Recruiting |
| NCT05824303 | Talazumab | Phase 1/2 | Recruiting |
| NCT04624799 | PAS-2221 | Preclinical | Active |
| NCT06058710 | Nirabrutinib | Phase 2 | Completed |
| NCT03771332 | Nirabrutinib | Phase 2 | Completed |
| NCT04520028 | TEM-5063 | Preclinical | Not yet recr... |
| NCT08430341 | CHA-IIT-687 | Phase 1 | Recruiting |